Congress orders audit of lung cancer research funding gaps
H.R. 6319 — Benay Taub Lung Cancer Research Act · Filed by Josh Gottheimer (D-NJ) · 4 cosponsors · Introduced Nov 28, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to create a Lung Cancer Task Force within the National Institutes of Health. The task force will study disparities in lung cancer research funding and patient access compared to other diseases, examine federal funding levels relative to disease burden, and review lung cancer screening practices. Within 180 days, it must report findings and recommendations to Congress, including suggestions for increasing federal funding for lung cancer research.
Why we flagged it
The bill is a straightforward directive to establish a task force to study lung cancer research funding and disparities. It is a transparency and fact-finding mechanism with no regulatory or appropriations component—purely a mandate to examine and report.
What the text implies
- Task force findings may reveal that lung cancer research is significantly underfunded relative to disease burden, potentially creating political pressure for substantial budget reallocations within NIH.
- The 180-day reporting deadline creates a near-term congressional trigger; if recommendations are compelling, they may drive supplemental appropriations or rebudgeting during the 119th Congress.
- Disparities analysis may expose gaps in screening access or treatment availability by geography or socioeconomic status, potentially informing future public health policy beyond research funding.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill creates a fact-finding mechanism that examines whether lung cancer research is underfunded relative to disease burden and identifies disparities in patient access. Citizens with lung cancer and the broader public benefit from transparency about research priorities and potential resource allocation gaps; the task force's recommendations may inform future funding decisions that improve treatment access and research outcomes.
Named in the bill
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Centers for Disease Control and Prevention, National Comprehensive Cancer Control Program
Where it stands
4 cosponsors: 3 Democrats, 1 Republicans.
- Nov 28, 2025 — Introduced · Congress.gov: “Introduced in House”
- Nov 28, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,265 characters) on Jun 8, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress orders audit of lung cancer research funding gaps” QuorumCivic. https://share.quorumcivic.app/bill/119/hr6319 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.